Hands On Most GenAI models are trained and run in massive datacenter clusters, but the ability to build, test, and prototype AI systems locally is no less relevant today. Until recently, this required ...
TransCode Therapeutics ( (RNAZ)) just unveiled an announcement. On December 19, 2025, TransCode Therapeutics appointed veteran life sciences executive Jack E. Stover to its board of directors, ...
BOSTON, Dec. 22, 2025 /PRNewswire/ -- TransCode Therapeutics, Inc. (NASDAQ: RNAZ), a clinical stage company pioneering immuno-oncology and RNA for the treatment of high risk and advanced cancer, ...
BOSTON - TransCode Therapeutics, Inc. (NASDAQ:RNAZ), a micro-cap biotech company with a market capitalization of just $7.91 million, and Quantum Leap Healthcare Collaborative announced Thursday a ...
BOSTON, Dec. 11, 2025 /PRNewswire/ -- TransCode Therapeutics, Inc. (NASDAQ: RNAZ) and Quantum Leap Healthcare Collaborative ("Quantum Leap") today announce a new collaboration to evaluate TransCode's ...
Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence. TransCode Therapeutics ( (RNAZ)) has ...
(RTTNews) - TransCode Therapeutics (RNAZ) has entered into a definitive agreement to acquire Polynoma, a privately-held biotechnology immuno-oncology company. Polynoma is developing a late-stage ...
In a pair of deals, TransCode Therapeutics has bagged Polynoma and its phase 3 cancer vaccine, as well as a $25 million injection into its cash-strapped coffers—but in doing so, the company is trading ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback